BE2017C027I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2017C027I2 BE2017C027I2 BE2017C027C BE2017C027C BE2017C027I2 BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2 BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56792104P | 2004-05-03 | 2004-05-03 | |
| US11/601,451 US8658203B2 (en) | 2004-05-03 | 2006-11-17 | Liposomes useful for drug delivery to the brain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2017C027I2 true BE2017C027I2 (instruction) | 2024-08-08 |
Family
ID=46045566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2017C027C BE2017C027I2 (instruction) | 2004-05-03 | 2017-07-10 |
Country Status (2)
| Country | Link |
|---|---|
| US (3) | US8658203B2 (instruction) |
| BE (1) | BE2017C027I2 (instruction) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811971B (zh) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| CN1960729B (zh) * | 2004-06-01 | 2012-04-11 | 泰尔茂株式会社 | 伊立替康制剂 |
| SI1807009T1 (sl) * | 2004-10-05 | 2015-04-30 | Genzyme Corporation | Stopničasta kanila |
| AU2006283189B2 (en) | 2005-08-23 | 2013-01-31 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
| US20140335166A1 (en) * | 2013-05-08 | 2014-11-13 | Michael W. Fountain | Methods of Making and Using Nano Scale Particles |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| WO2009033176A1 (en) * | 2007-09-07 | 2009-03-12 | The Trustees Of The University Of Pennsylvania | A method of targeting a transferrin receptor |
| US9550827B2 (en) | 2007-10-19 | 2017-01-24 | The Regents Of The University Of California | Methods for ameliorating and preventing central nervous system inflammation |
| US20100284912A1 (en) * | 2007-12-04 | 2010-11-11 | Bracco Diagnostics Inc. | Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients |
| AR076634A1 (es) * | 2008-11-21 | 2011-06-29 | Medgenesis Therapeutix Inc | Composiciones y metodo para tratar desordenes del sistema nervioso central |
| JP5588619B2 (ja) | 2009-03-11 | 2014-09-10 | 一丸ファルコス株式会社 | pH応答性リポソーム |
| DE102009031274A1 (de) * | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
| EP2558154B1 (en) | 2010-04-16 | 2020-06-17 | ClearPoint Neuro, Inc. | Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient |
| EP2582358B1 (en) * | 2010-06-19 | 2019-04-17 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| CN104523565A (zh) * | 2010-11-26 | 2015-04-22 | 约翰内斯堡威特沃特斯兰德大学 | 用于治疗精神分裂症的可植入头颅中的装置 |
| US10980798B2 (en) * | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| ES2660492T3 (es) | 2012-02-14 | 2018-03-22 | The Regents Of The University Of California | Administración sistémica y expresión regulada de genes paracrinos para enfermedades cardiovasculares y otras afecciones |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014039504A1 (en) * | 2012-09-04 | 2014-03-13 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
| US20150306236A1 (en) * | 2012-09-04 | 2015-10-29 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
| WO2014116866A1 (en) * | 2013-01-24 | 2014-07-31 | Memorial Sloan Kettering Cancer Center | Method for diagnosing or treating tumors using sphingomyelin containing liposomes |
| ES2964512T3 (es) * | 2013-02-01 | 2024-04-08 | Celator Pharmaceuticals Inc | Carga remota de fármacos escasamente solubles en agua en liposomas |
| US9289502B2 (en) | 2013-03-08 | 2016-03-22 | Emerald Therapeutics, Inc. | Preparation of oligo conjugates |
| EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
| US9891296B2 (en) | 2013-09-13 | 2018-02-13 | MRI Interventions, Inc. | Intrabody fluid transfer devices, systems and methods |
| US20160166651A1 (en) | 2014-04-03 | 2016-06-16 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure |
| US10004759B2 (en) | 2014-08-04 | 2018-06-26 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
| US20160158154A1 (en) * | 2014-12-05 | 2016-06-09 | Georgia Tech Research Corporation | Protein vesicles and methods of making and using thereof |
| AU2015360761B2 (en) * | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| US11260126B2 (en) * | 2015-08-21 | 2022-03-01 | University Of Otago | Acoustic driven drug delivery systems |
| ES2826826T3 (es) | 2015-08-21 | 2021-05-19 | Ipsen Biopharm Ltd | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático |
| US10123969B2 (en) | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
| KR20180063255A (ko) * | 2015-10-16 | 2018-06-11 | 입센 바이오팜 리미티드 | 캄프토테신 제약 조성물의 안정화 |
| EP3386527B1 (en) | 2015-12-10 | 2021-05-26 | The Regents of the University of California | Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
| EP3393571B1 (en) | 2016-02-17 | 2024-03-06 | ClearPoint Neuro, Inc. | Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
| EP3655021B1 (en) | 2017-07-19 | 2023-03-22 | Unikeris Limited | Adenosine deaminase for treating or ameliorating scleroderma-associated vasculopathy |
| JP6974587B2 (ja) | 2017-08-09 | 2021-12-01 | 中興通訊股▲ふん▼有限公司Zte Corporation | ユーザプレーンを分離するためのサービス実装の品質 |
| JP6297737B1 (ja) * | 2017-09-25 | 2018-03-20 | ジェイ−ネットワーク,インコーポレイテッド | 正に帯電した荷電ニオソームの調製方法及び荷電ニオソーム |
| US20210113595A1 (en) * | 2018-04-30 | 2021-04-22 | Purdue Research Foundation | Liposomal nano formulation of combinational antibiotics and the uses thereof |
| EP3781074A1 (en) | 2018-05-09 | 2021-02-24 | ClearPoint Neuro, Inc. | Mri compatible intrabody fluid transfer systems and related devices and methods |
| US11253237B2 (en) | 2018-05-09 | 2022-02-22 | Clearpoint Neuro, Inc. | MRI compatible intrabody fluid transfer systems and related devices and methods |
| ES2949701T3 (es) | 2018-07-26 | 2023-10-02 | Cvie Therapeutics Ltd | Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca |
| TWI729562B (zh) * | 2018-11-14 | 2021-06-01 | 台灣微脂體股份有限公司 | 包含用於治療因骨密度降低或軟骨損失導致之疾病的治療劑的緩釋藥物組合物及其用途 |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| KR20210136048A (ko) | 2019-03-05 | 2021-11-16 | 윈드트리 세라퓨틱스, 인크. | 급성 심부전 (ahf)의 치료를 위한 이스타록심-함유 정맥내 제형 |
| CA3144725A1 (en) * | 2019-08-01 | 2021-02-04 | Mir Imran | Intracranial delivery of medicinal solution |
| US11684750B2 (en) | 2019-10-08 | 2023-06-27 | Clearpoint Neuro, Inc. | Extension tube assembly and related medical fluid transfer systems and methods |
| FI3805243T3 (fi) | 2019-10-09 | 2024-02-07 | Windtree Therapeutics Inc | Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon |
| EP4213810A4 (en) * | 2020-09-16 | 2025-06-18 | Imagion Biosystems, Inc. | Methods and apparatuses for the synthesis of drug-loaded magnetic micelle aggregates |
| CN116829142A (zh) | 2021-02-01 | 2023-09-29 | 加利福尼亚大学董事会 | 处理和改善癌症的方法 |
| US20240209341A1 (en) | 2021-03-18 | 2024-06-27 | The Regents Of The University Of California | Compositions and methods for targeting inflammatory or activated cells and treating or ameliorating inflammatory conditions and pain |
| CN115364218A (zh) * | 2021-05-21 | 2022-11-22 | 杭州高田生物医药有限公司 | 一种特定药脂比的药物组合物在抗肿瘤中的应用 |
| WO2023004113A2 (en) | 2021-07-22 | 2023-01-26 | The Regents Of The University Of California | Compositions and methods for using purified human rna editing enzymes |
| EP4452268A1 (en) * | 2021-12-22 | 2024-10-30 | MyCural Therapeutics AB | Novel pyridocarbazolium compounds and medical uses thereof |
| TW202345828A (zh) * | 2022-03-31 | 2023-12-01 | 日商衛材R&D企管股份有限公司 | 脂質體組合物及包含脂質體之醫藥組合物 |
| CN119119030A (zh) * | 2023-06-08 | 2024-12-13 | 西南大学 | 长春胺类衍生物及其制备方法和应用 |
| CN116874540A (zh) * | 2023-07-20 | 2023-10-13 | 上海灵瑞医药有限公司 | 硫酸酯三乙铵盐的合成方法 |
| WO2025076208A1 (en) | 2023-10-03 | 2025-04-10 | Raft Pharmaceuticals, Inc. | Compositions and methods for treating pain disorders |
| CN119909018B (zh) * | 2025-04-01 | 2025-09-02 | 山东新时代药业有限公司 | 一种注射用氟维司群长效脂质体及其制备方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578987A (en) * | 1897-03-16 | Mechanism for propelling vessels | ||
| DE2740053A1 (de) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| US4192869A (en) | 1977-09-06 | 1980-03-11 | Studiengesellschaft Kohle Mbh. | Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles |
| US4397846A (en) | 1981-05-15 | 1983-08-09 | Murray Weiner | Storage-stable lipid vesicles and method of preparation |
| US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
| IL72420A (en) | 1983-07-22 | 1987-10-30 | Hoffmann La Roche | Aqueous vitamin e solutions and their manufacture |
| US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| PL296382A1 (en) | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| AU654835B2 (en) | 1991-07-03 | 1994-11-24 | Nexstar Pharmaceuticals, Inc. | Loading technique for preparing drug containing liposomes |
| US5281237A (en) * | 1992-09-25 | 1994-01-25 | Gimpelson Richard J | Surgical stitching device and method of use |
| US6350853B1 (en) * | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4320597A1 (de) | 1993-06-22 | 1995-01-05 | Heinz C Prof Dr Dr Schroeder | Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren |
| US6743917B2 (en) * | 1993-06-30 | 2004-06-01 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
| US5538954A (en) * | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| JP3203358B2 (ja) * | 1994-02-04 | 2001-08-27 | リポコーア・ホールディング・アクチエボラーグ | 二重層製剤 |
| US5783568A (en) * | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4981896A (en) | 1995-02-14 | 1996-09-04 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| AU2284697A (en) | 1996-04-11 | 1997-10-29 | University Of British Columbia, The | Fusogenic liposomes |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6110491A (en) * | 1996-10-22 | 2000-08-29 | Hermes Biosciences, Inc. | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| EP1005327A1 (en) | 1997-07-02 | 2000-06-07 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
| US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| US6083923A (en) | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
| RU2130771C1 (ru) | 1998-06-01 | 1999-05-27 | Автушенко Сергей Сергеевич | Способ получения липосомальных препаратов |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| AU1678900A (en) | 1998-08-11 | 2000-03-06 | All India Institute Of Medical Sciences | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases |
| WO2000009089A1 (en) | 1998-08-12 | 2000-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
| PT1121102E (pt) | 1998-09-16 | 2003-09-30 | Alza Corp | Inibidores da topoisomerase aprisionados em lipossoma |
| US6291676B1 (en) * | 1999-03-03 | 2001-09-18 | University Of Kentucky Research Foundation | Water-soluble derivatives of camptothecin/homocamptothecin |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| CN1172670C (zh) | 1999-04-29 | 2004-10-27 | 阿尔萨公司 | 用于改善药物保留的脂质体组合物 |
| US20020049176A1 (en) * | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
| ATE341310T1 (de) | 2000-02-04 | 2006-10-15 | Lipoxen Technologies Ltd | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
| JP4679028B2 (ja) | 2000-05-15 | 2011-04-27 | セルジーン コーポレイション | 結腸直腸癌を治療するための組成物および方法 |
| US6486320B2 (en) | 2000-09-15 | 2002-11-26 | Aventis Pharma S.A. | Preparation of camptothecin and of its derivatives |
| WO2002036073A2 (en) | 2000-11-02 | 2002-05-10 | Smithkline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| AU2002305094B2 (en) | 2001-03-26 | 2007-01-11 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| TWI235066B (en) * | 2001-10-03 | 2005-07-01 | Celator Technologies Inc | Liposome loading with metal ions |
| US20030129224A1 (en) * | 2001-11-13 | 2003-07-10 | Paul Tardi | Lipid carrier compositions and methods for improved drug retention |
| US20030220284A1 (en) * | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| CA2488230C (en) | 2002-04-29 | 2013-04-09 | Yves Claude Nicolau | Inositol pyrophosphates, and methods of use thereof |
| ES2354607T3 (es) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| US20040243101A1 (en) * | 2002-07-02 | 2004-12-02 | Gillis Edward M. | Minimally invasive drug delivery catheter |
| AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| US20040170677A1 (en) | 2002-11-26 | 2004-09-02 | Ning Hu | Method of drug loading in liposomes by gradient |
| EP1643972A4 (en) | 2003-06-27 | 2010-01-20 | Smithkline Beecham Corp | STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD |
| AU2004264857B2 (en) * | 2003-07-09 | 2010-06-10 | Sutter West Bay Hospitals | Remote detection of substance delivery to cells |
| CN107811971B (zh) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| SI1807009T1 (sl) * | 2004-10-05 | 2015-04-30 | Genzyme Corporation | Stopničasta kanila |
| US20060129126A1 (en) * | 2004-11-19 | 2006-06-15 | Kaplitt Michael G | Infusion device and method for infusing material into the brain of a patient |
| WO2006069181A2 (en) * | 2004-12-21 | 2006-06-29 | Musc Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
-
2006
- 2006-11-17 US US11/601,451 patent/US8658203B2/en active Active
-
2014
- 2014-01-09 US US14/151,632 patent/US20140127136A1/en not_active Abandoned
-
2016
- 2016-10-18 US US15/296,536 patent/US9737528B2/en not_active Expired - Lifetime
-
2017
- 2017-07-10 BE BE2017C027C patent/BE2017C027I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9737528B2 (en) | 2017-08-22 |
| US8658203B2 (en) | 2014-02-25 |
| US20140127136A1 (en) | 2014-05-08 |
| US20070110798A1 (en) | 2007-05-17 |
| US20170035749A1 (en) | 2017-02-09 |